Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Lancet

Retrieve available abstracts of 42 articles:
HTML format

Single Articles

    June 2023
  1. BEARDMORE-GRAY A, Vousden N, Seed PT, Vwalika B, et al
    Planned delivery or expectant management for late preterm pre-eclampsia in low-income and middle-income countries (CRADLE-4): a multicentre, open-label, randomised controlled trial.
    Lancet. 2023 Jun 29:S0140-6736(23)00688-8. doi: 10.1016/S0140-6736(23)00688.
    PubMed     Abstract available

    Evidence in favour of ambulatory blood pressure grows but gaps in knowledge remain.
    Lancet. 2023;401:2014-2015.

  3. STAPLIN N, de la Sierra A, Ruilope LM, Emberson JR, et al
    Relationship between clinic and ambulatory blood pressure and mortality: an observational cohort study in 59 124 patients.
    Lancet. 2023;401:2041-2050.
    PubMed     Abstract available

  4. PLATZBECKER U, Della Porta MG, Santini V, Zeidan AM, et al
    Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
    Lancet. 2023 Jun 9:S0140-6736(23)00874-7. doi: 10.1016/S0140-6736(23)00874.
    PubMed     Abstract available

    April 2023
  5. DIXON SB, Liu Q, Chow EJ, Oeffinger KC, et al
    Specific causes of excess late mortality and association with modifiable risk factors among survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort.
    Lancet. 2023;401:1447-1457.
    PubMed     Abstract available

  6. BHATT DL, Bakris GL
    Key questions regarding the SYMPLICITY HTN-3 trial - Authors' reply.
    Lancet. 2023;401:1337-1338.

    Key questions regarding the SYMPLICITY HTN-3 trial.
    Lancet. 2023;401:1337.

  8. KJELDSEN SE, Burnier M, Narkiewicz K, Kreutz R, et al
    Key questions regarding the SYMPLICITY HTN-3 trial.
    Lancet. 2023;401:1336-1337.

    March 2023
  9. HE J, Ouyang N, Guo X, Sun G, et al
    Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial.
    Lancet. 2023 Mar 2:S0140-6736(22)02603-4. doi: 10.1016/S0140-6736(22)02603.
    PubMed     Abstract available

    December 2022
  10. KRAMER CK, Leitao CB, Viana LV
    The impact of urbanisation on the cardiometabolic health of Indigenous Brazilian peoples: a systematic review and meta-analysis, and data from the Brazilian Health registry.
    Lancet. 2022;400:2074-2083.
    PubMed     Abstract available

    November 2022
  11. WEATHERALD J, Boucly A, Peters A, Montani D, et al
    The evolving landscape of pulmonary arterial hypertension clinical trials.
    Lancet. 2022;400:1884-1898.
    PubMed     Abstract available

  12. SCHLAICH MP, Bellet M, Weber MA, Danaietash P, et al
    Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.
    Lancet. 2022 Nov 4. pii: S0140-6736(22)02034.
    PubMed     Abstract available

  13. DECHEND R, Delles C
    Endothelin antagonists and the quest for a new therapeutic option in resistant hypertension.
    Lancet. 2022 Nov 4. pii: S0140-6736(22)02181.

    October 2022
  14. FANELLI E, Persu A
    SYMPLICITY HTN-3: failure at 6 months, success at 3 years?
    Lancet. 2022;400:1382-1383.

  15. SALAH HM, Mehta JL
    Best time for administration of antihypertensive medications: morning or evening?
    Lancet. 2022 Oct 11. pii: S0140-6736(22)01900.

  16. MACKENZIE IS, Rogers A, Poulter NR, Williams B, et al
    Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial.
    Lancet. 2022 Oct 11. pii: S0140-6736(22)01786.
    PubMed     Abstract available

    September 2022
  17. BHATT DL, Vaduganathan M, Kandzari DE, Leon MB, et al
    Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.
    Lancet. 2022 Sep 16. pii: S0140-6736(22)01787.
    PubMed     Abstract available

  18. CLAASSEN J, Park S
    Spontaneous subarachnoid haemorrhage.
    Lancet. 2022;400:846-862.
    PubMed     Abstract available

    May 2022
  19. SUN Y, Mu J, Wang DW, Ouyang N, et al
    A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trial.
    Lancet. 2022;399:1964-1975.
    PubMed     Abstract available

    April 2022
  20. FIZAZI K, Foulon S, Carles J, Roubaud G, et al
    Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design.
    Lancet. 2022;399:1695-1707.
    PubMed     Abstract available

  21. JAFAR TH, Jabbour S
    Village doctors managing hypertension in rural China.
    Lancet. 2022 Apr 29. pii: S0140-6736(22)00424.

  22. MAHFOUD F, Kandzari DE, Kario K, Townsend RR, et al
    Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial.
    Lancet. 2022;399:1401-1410.
    PubMed     Abstract available

  23. SARATHY H, Salman LA
    Can renal denervation replace medications for patients with hypertension?
    Lancet. 2022;399:1363-1365.

  24. WALD NJ, Law M, Morris J, Wald DS, et al
    Blood pressure meta-analysis highlights an implementation gap.
    Lancet. 2022;399:1379-1380.

    November 2021
  25. CAVENDER MA, Wirka RC
    Blood pressure lowering in the prevention of type 2 diabetes.
    Lancet. 2021;398:1778-1779.

  26. NAZARZADEH M, Bidel Z, Canoy D, Copland E, et al
    Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis.
    Lancet. 2021;398:1803-1810.
    PubMed     Abstract available

  27. GARRISON SR, McCormack J
    Blood pressure treatment: how low should you go?
    Lancet. 2021;398:1684.

    September 2021
  28. PEARLMAN B, Lodebo BT
    Renin secreting tumour: a rare cause of secondary hypertension.
    Lancet. 2021;398:1074.

  29. KAHAN T
    Low-dose combination of blood pressure-lowering medicines.
    Lancet. 2021;398:1022-1023.

  30. NGUYEN TN, Chow CK
    Global and national high blood pressure burden and control.
    Lancet. 2021;398:932-933.

  31. JAFFAR S, Ramaiya K, Karekezi C, Sewankambo N, et al
    Controlling diabetes and hypertension in sub-Saharan Africa: lessons from HIV programmes.
    Lancet. 2021 Sep 7. pii: S0140-6736(21)01731.

    August 2021
  32. CHOW CK, Atkins ER, Hillis GS, Nelson MR, et al
    Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial.
    Lancet. 2021 Aug 27. pii: S0140-6736(21)01922.
    PubMed     Abstract available

  33. JACKSON R, Wells S
    Time to remove hypertension from our vocabulary?
    Lancet. 2021 Aug 26. pii: S0140-6736(21)01916.

  34. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
    Lancet. 2021 Aug 26. pii: S0140-6736(21)01921.
    PubMed     Abstract available

  35. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.
    Lancet. 2021 Aug 24. pii: S0140-6736(21)01330.
    PubMed     Abstract available

    July 2021
  36. AFIFI T, Obeid M, Abdelati M, Almoqaid A, et al
    WHO/International Society of Hypertension risk prediction charts versus the UK Prospective Diabetes Study risk engine for cardiovascular risk assessment among patients with type 2 diabetes: a comparative study.
    Lancet. 2021;398 Suppl 1:S3.
    PubMed     Abstract available

    Effect of hypertension on pregnancy outcomes at UNRWA health centres in Gaza governorates: a comparative study.
    Lancet. 2021;398 Suppl 1:S26.
    PubMed     Abstract available

    May 2021
  38. BROUWERS S, Sudano I, Kokubo Y, Sulaica EM, et al
    Arterial hypertension.
    Lancet. 2021 May 18. pii: S0140-6736(21)00221.
    PubMed     Abstract available

  39. AZIZI M, Sanghvi K, Saxena M, Gosse P, et al
    Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial.
    Lancet. 2021 May 14. pii: S0140-6736(21)00788.
    PubMed     Abstract available

  40. KAHAN T
    Decisions about antihypertensive treatment should focus on reducing cardiovascular risk.
    Lancet. 2021;397:1598-1599.

  41. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
    Lancet. 2021;397:1625-1636.
    PubMed     Abstract available

    March 2021
  42. FIGTREE GA, Vernon ST, Hadziosmanovic N, Sundstrom J, et al
    Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.
    Lancet. 2021;397:1085-1094.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hypertension is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.